Post Market Surveillance Report (PMSR) under EU MDR
A Post Market Surveillance Report (PMSR) is the document in which a Class I medical device manufacturer summarises the results and conclusions of its post-market surveillance data, with the reasons for any preventive or corrective action taken. It is required by Article 85 of EU MDR 2017/745. Class IIa, IIb and III devices need a Periodic Safety Update Report (PSUR) instead. This guide explains what the report must contain, how often it is updated, how it differs from the PSUR and how I3CGLOBAL prepares it.
Definition
What Is a Post Market Surveillance Report?
Under Article 85 of EU MDR 2017/745, manufacturers of Class I devices must prepare a post-market surveillance report. The report summarises the results and conclusions of the analysis of the data gathered under the Post Market Surveillance Plan. It also gives the rationale for, and a description of, any preventive and corrective actions taken.
The report is not written once and filed. The manufacturer updates it when necessary and makes it available to the competent authority on request. Together with the PMS Plan, it forms the post-market surveillance part of the technical documentation described in Annex III of the MDR.

Legal basis
What Does MDR Article 83 Require of the PMS System?
The report is the output of a system. Article 83 requires every manufacturer to plan, establish, document, implement, maintain and update a post-market surveillance system for each device. The system must be proportionate to the risk class and appropriate for the type of device, and it is an integral part of the quality management system.
Article 83 lists what the collected data must be used for:
- Updating the benefit-risk determination and improving risk management.
- Updating the design and manufacturing information, the instructions for use and the labelling.
- Updating the clinical evaluation.
- Updating the summary of safety and clinical performance, where one is required.
- Identifying the need for preventive, corrective or field safety corrective action.
- Identifying options to improve the usability, performance and safety of the device.
- Contributing, where relevant, to the post-market surveillance of other devices.
- Detecting and reporting trends under Article 88.
A PMS Report is convincing only when it shows that these uses of the data actually happened during the reporting period.
Content
What Should a Post Market Surveillance Report Contain?
Article 85 sets the minimum content. In practice, Notified Bodies and competent authorities expect a report that a reviewer can follow from data to conclusion. We structure a PMS Report in six parts.
- Device and periodThe devices covered, their Basic UDI-DI, risk class and the data collection period.
- Data sources usedThe proactive and reactive sources named in the PMS Plan, and any source that produced no data.
- ResultsComplaints, non-serious incidents, serious incidents, field safety corrective actions, literature and information on similar devices.
- AnalysisRates compared with the indicators and threshold values set in the PMS Plan, and any trend identified.
- ConclusionsWhether the benefit-risk determination is still valid and whether any document needs to be updated.
- ActionsEach preventive or corrective action, with its rationale and status.
The conclusions must then be carried into the Clinical Evaluation Report, the risk management file and the checklist of general safety and performance requirements.
By device class
PMSR vs PSUR: Which Report Does Each Device Class Need?
The reporting document, its update frequency and who receives it all depend on the risk class of the device. A manufacturer does not prepare both documents for the same device.
| Device class | Document | Update frequency | Who receives it |
|---|---|---|---|
| Class I | PMS Report (Article 85) | When necessary | Competent authority, on request |
| Class IIa | PSUR (Article 86) | When necessary and at least every two years | Notified Body involved in the conformity assessment; competent authority on request |
| Class IIb | PSUR (Article 86) | At least annually | Notified Body involved in the conformity assessment; competent authority on request |
| Class III | PSUR (Article 86) | At least annually | Submitted to the Notified Body, which reviews it and adds its evaluation |
PSURs for implantable devices are also submitted to the Notified Body for review, whatever their class. Article 86 foresees submission through EUDAMED.
The PSUR also goes further in content. It must include the conclusions of the benefit-risk determination, the main findings of post-market clinical follow-up (PMCF), the volume of sales, and an estimate of the size and characteristics of the population using the device. For the full requirements, see our Periodic Safety Update Report (PSUR) page.
Integration
How Does the PMS Report Connect to the QMS and Technical Documentation?
The PMS Report draws on, and feeds, several other documents. An auditor will check that they agree with each other.
| Document | Relationship to the PMS Report |
|---|---|
| Post Market Surveillance Plan | Defines the data sources, methods, indicators and thresholds that the report must follow (Article 84 and Annex III). |
| Post Market Surveillance SOP | The quality system procedure that sets who collects, analyses and reports the data. |
| Clinical Evaluation Report | Updated with the post-market data summarised in the report. |
| Risk management file (ISO 14971) | New hazards, changed occurrence rates and new risk controls are fed back from the report. |
| PMCF plan and report | PMCF is the clinical part of post-market surveillance. Its findings are inputs to the report. |
| ISO 13485:2016, clause 8.2.1 | Feedback from production and post-production activities is a required input to the quality management system. |
Under Article 15 of the MDR, the person responsible for regulatory compliance (PRRC) must ensure that the post-market surveillance obligations are met.
Vigilance
How Do Vigilance and Trend Reporting Relate to the PMS Report?
The PMS Report does not replace vigilance. Vigilance and trend reporting are separate obligations with their own deadlines. The PMS Report summarises them.
Serious incidents: Article 87
Reported to the competent authority no later than 15 days after the manufacturer becomes aware. The limit is 10 days for a death or an unanticipated serious deterioration in health, and 2 days for a serious public health threat.
Field safety corrective actions: Article 87
Reported before the action is taken, except in cases of urgency. Each action and its status is then listed in the PMS Report.
Trend reporting: Article 88
A statistically significant increase in the frequency or severity of non-serious incidents, or of expected undesirable side-effects, is reported as a trend.
The European Commission guidance MDCG 2025-10 on post-market surveillance of medical devices and in vitro diagnostic medical devices should be considered when the PMS system and its reports are prepared.
Devices sold in Great Britain must also meet the GB post-market surveillance requirements that have applied since 16 June 2025, with serious incidents and field safety corrective actions reported to the MHRA. Manufacturers outside the UK coordinate this with their UK Responsible Person.
Template
Is a Post Market Surveillance Report Template Available?
Yes. Manufacturers who prepare the report in-house can buy an editable Microsoft Word PMS Report template as part of our PMS documentation package. It is prepared for EU MDR 2017/745 and ISO 13485:2016, clause 8.2.1.
The package also contains the PMS procedure, the PMS Plan template and the supporting record forms. See the PMS documentation package for the full list and price.

Work with I3CGLOBAL
How Does I3CGLOBAL Prepare Your PMS Report?
Our regulatory team reviews your PMS Plan and data, performs the analysis, and writes or updates the PMS Report or PSUR so that it agrees with your clinical evaluation and risk management file. We work with manufacturers of all device classes, worldwide.
- Gap review of the existing PMS Plan against Annex III.
- Analysis of complaints, incidents, literature and similar-device data.
- PMS Report for Class I devices and PSUR for Class IIa, IIb and III devices.
- Alignment with the Clinical Evaluation Report, PMCF and risk management file.
- Support with Notified Body and competent authority questions.
Start your PMS Report
Send us your device list, risk classes and the reporting period. We reply with a scope, timeline and fee.
FAQs
Post Market Surveillance Report: Frequently Asked Questions
What is a Post Market Surveillance Report under EU MDR 2017/745?
A Post Market Surveillance Report is a mandatory regulatory document required under Article 85 of EU MDR 2017/745 for Class I medical device manufacturers. It summarizes the results of all post-market surveillance activities conducted over a defined period, evaluates the continued safety and performance of the device, and updates the benefit-risk analysis based on real-world data.
The PMSR must be prepared based on the PMS Plan (Article 84) and must form part of the MDR technical documentation. Class IIa, IIb, and Class III devices require a Periodic Safety Update Report (PSUR) under Article 86 rather than a PMSR.
Is a PMSR mandatory for all medical device manufacturers under MDR?
Yes. All medical device manufacturers placing devices on the EU market under MDR 2017/745 are required to maintain a post market surveillance system and produce either a PMSR (for Class I devices, under Article 85) or a PSUR (for Class IIa, IIb, and III devices, under Article 86). There are no exemptions based on device size, volume, or manufacturer location. The absence of an up-to-date PMSR or PSUR is treated as a major non-conformity during Notified Body audits and Competent Authority inspections.
How often must the Post Market Surveillance Report be updated?
The update frequency depends on device class. For Class I devices, the PMSR must be updated whenever significant new information is available — there is no fixed frequency, but it must always be current and available upon request by authorities. For Class IIa devices, the PSUR must be updated at least every two years. For Class IIb and Class III devices, the PSUR must be updated annually. In all cases, the report must reflect the most recent post-market surveillance data and any changes to the device’s benefit-risk profile.
What is the difference between a PMSR and a PSUR under MDR?
Both documents are outputs of the post market surveillance system, but they differ in scope, frequency, and the device classes they apply to. The PMSR (Post Market Surveillance Report) under Article 85 applies to Class I medical devices and is updated when significant new data becomes available. The PSUR (Periodic Safety Update Report) under Article 86 applies to Class IIa, IIb, and Class III devices and must be updated annually (Class IIb/III) or every two years (Class IIa). The PSUR is more detailed and must include sales volume data, an estimate of the population exposed to the device, and the main findings of the post-market surveillance activities.
What data sources must be included in a medical device post market surveillance report?
A compliant MDR Post Market Surveillance Report must draw from both reactive and proactive data sources. Reactive sources include customer complaints, field safety corrective actions (FSCAs), adverse event reports, literature reviews, service and maintenance records, and device registry data. Proactive sources include customer surveys, PMCF studies, implant registry data, expert user group consultations, and benchmarking against similar devices on the market. The PMS Plan must define how data from all these sources is collected, recorded, analyzed, and used to update the benefit-risk assessment and the GSPR checklist.
How is the Post Market Surveillance Report connected to the Clinical Evaluation Report (CER)?
The Post Market Surveillance Report and the Clinical Evaluation Report (CER) are directly connected in a continuous regulatory feedback loop under EU MDR 2017/745. Post-market surveillance data — including real-world performance data, complaint trends, and PMCF study results — must be fed back into the CER to keep it current. The PMSR or PSUR provides the post-market evidence that updates the clinical claims, benefit-risk conclusions, and the state-of-the-art assessment within the CER. A CER that is not updated with PMSR findings will be considered non-compliant during Notified Body review.
Can I3CGlobal prepare our Post Market Surveillance Report and PMS Plan?
Yes. I3CGlobal is a specialist medical device PMS consultancy with extensive experience preparing Post Market Surveillance Reports (PMSR), PMS Plans, and Periodic Safety Update Reports (PSUR) for medical device manufacturers seeking MDR CE Marking. Our team of regulatory consultants prepares all PMS documentation in compliance with EU MDR 2017/745, Annex III, ISO 13485:2016, and MDCG guidance. We support manufacturers across all device classes — Class I, IIa, IIb, and III — and work alongside your clinical evaluation, technical documentation, and quality teams to deliver a fully integrated PMSR that will withstand Notified Body scrutiny.
What happens if my Post Market Surveillance Report is missing or out of date?
A missing or outdated Post Market Surveillance Report is treated as a major non-conformity under EU MDR 2017/745. During a Notified Body technical file review or QMS audit, auditors will specifically check for a current, evidence-based PMSR or PSUR. If it is absent, incomplete, or not updated in response to new data, the Notified Body may issue a major non-conformity finding, which can delay or block your CE Marking certificate. In severe cases, Competent Authorities can also require market withdrawal of non-compliant devices. Manufacturers should treat the PMSR as a living document that is continuously maintained, not a one-time exercise.
